Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dutch reimburse cervical cancer heat therapy:

This article was originally published in Clinica

Executive Summary

The treatment of advanced cervical cancer using deep regional hyperthermia and radiation has been approved for reimbursement in the Netherlands. The Dutch parliament has also confirmed deep hyperthermia as the treatment of first choice for advanced cervical cancer. The move follows the positive outcome of a study on the heat therapy carried out at the University Medical School of Rotterdam. The clinical trial used the BSD-2000 system, developed by US company BSD Medical, to treat deep cervical tumours. Deep regional hyperthermia as an adjunct to cervical cancer treatment is already reimbursed in the German states of Bavaria, Berlin and Baden-Wurttemberg.

You may also be interested in...



Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market

Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.

Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations

Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel